On November 11, 2021 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) reported the financial results and corporate updates for the first nine months 2021 (Press release, Evotec, NOV 11, 2021, View Source [SID1234595240]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
HIGHLIGHTS
STRONG REVENUES GROWTH IN ALL BUSINESS AREAS FUELS ONGOING EXPANSION AND STRENGTHENS POSITIVE DEVELOPMENT
Group revenues increased by 20% to € 431.0 m (9M 2020: € 360.4 m); like-for-like base revenue growth (excluding portfolio and fx effects) up 26%
Milestone revenues of € 27.9 m well above last year (9M 2020: € 8.4 m)
Just – Evotec Biologics contributed € 34.7 m to revenues; 43% above last year’s level of € 24.3 m
Strong progress in both segments: Total EVT Execute revenues up 17% to € 429.8 m (9M 2020: € 367.5 m); EVT Innovate revenues up 35% to € 101.9 m (9M 2020: € 75.7 m)
Adjusted Group EBITDA of € 70.1 m (9M 2020: € 76.9 m) primarily driven by higher costs of sales ahead of production start of J.POD Redmond (US), a deliberate increase in unpartnered R&D (up 28%), the overall growth of Evotec and effects from the US public offering; like-for-like growth (excluding portfolio and fx effects) would have reached 16%.
Other non-operating result increased significantly to € 228.8 m (9M 2020: € (15.9) m) mainly due to fair value adjustments of the equity participation in Exscientia Ltd.
DATA-DRIVEN AUTOBAHN TO CURES: STRONG PROGRESS IN ALL LANES
Several new and extended drug discovery and development agreements in all areas
Just – Evotec Biologics opened J.POD Redmond (US); start operations on track; project initiation of J.POD Toulouse (France) in 2021
Positive Phase IIb results in refractory chronic cough for eliapixant reported by partner Bayer
Excellent progress in iPSC and protein degradation collaborations with Bristol Myers Squibb ("BMS"); Opt-in for EVT8683 to enter clinical development
Kazia Therapeutics Limited has commenced enrolment to a Phase I clinical trial of EVT801, an investigational cancer therapy (after period-end)
Successful NASDAQ IPO of EVOequity portfolio company and partner Exscientia Ltd (after period-end); Series B extension by Evotec’s first spin-off Topas Therapeutics
CORPORATE
Closing of public offering at NASDAQ on 08 November 2021, with notice from underwriters on 05 November 2021 of their intention to partially exercise their option to purchase additional ADSs (after period-end)
CONFIRMATION OF BUSINESS OUTLOOK FOR FULL-YEAR 2021 AND MID-TERM TARGETS 2025
Group revenues expected to be in a range of € 550 – 570 m (€ 565 – 585 m at constant exchange rates) (2020: € 500.9 m)
Adjusted Group EBITDA expected to be in the range of € 105 – 120 m (€ 115 – 130 m at constant exchange rates) (2020: € 106.6 m)
Unpartnered research and development expenses expected to be in a range of € 50 – 60 m (2020: € 46.4 m)
Mid-term goals target revenue growth to > € 1,000 m, adjusted EBITDA of ≥ € 300 m and unpartnered research and development expenses of > € 100 m by 2025
Given current global insecurities surrounding the COVID-19 pandemic, a likely negative impact – though less pronounced than in 2020 – is already estimated within the guidance for revenues and adjusted EBITDA stated above.
More detailed information and financial tables are available in our nine-month report published on the Evotec website under the following link:
View Source
WEBCAST / CONFERENCE CALL
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.
A simultaneous slide presentation for participants dialling in via phone is available at View Source
Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our homepage View Source shortly before the event.
The access code is 315614529#. The on-demand version of the webcast will be available on our website: View Source and under the direct link View Source